Spyre Therapeutics, Inc. SYRE Business Segments — Other segment items
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s business segments — other segment items.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s business segments — other segment items?
- Spyre Therapeutics, Inc. (SYRE) reported business segments — other segment items of -$2.14M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s business segments — other segment items changed year-over-year?
- Spyre Therapeutics, Inc.'s business segments — other segment items increased by 53.8% year-over-year, from -$4.63M to -$2.14M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s business segments — other segment items?
- Over 2 years (2022 to 2024), Spyre Therapeutics, Inc.'s business segments — other segment items has grown at a 10.2% compound annual growth rate (CAGR), from $12.56M to $15.26M.
- What does business segments — other segment items mean?
- Residual operational income or expenses within the segment that do not fall into standard categories like R&D or compensation. This often includes one-time charges, gains on asset sales, or miscellaneous overhead allocations.